peptide backbone raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-14. Anything still debated is marked as such rather than presented as settled.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Includes the 39-residue backbone and the attached fatty diacid |
| Molecular weight | Approximately 4813 Da | Average mass; the monoisotopic value is slightly lower |
| Receptor targets | GIP receptor and GLP-1 receptor | Dual engagement defines the pharmacological class |
| Backbone length | 39 amino acids | Sequence modified from native glucose-dependent insulinotropic polypeptide |
| Albumin interaction | Reversible, mediated by the fatty diacid | Slows renal clearance and lengthens circulation time |
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
Cold-chain handling is standard for formulated product, with dry powder stored frozen and ready-to-use solutions refrigerated. Light exposure is minimized because photodegradation of certain amino acid side chains is possible. Shipping and temperature-excursion studies are used to establish whether short deviations affect quality attributes. Documentation supplied with research material usually includes a certificate of analysis listing purity, identity confirmation, and water or residual solvent content. Users are expected to confirm that material meets the stated specification before use.
Identity and purity of tirzepatide are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Because the molecule carries several modifications, gradient conditions are adjusted to resolve the intact peptide from deamidation and oxidation products. Enzymatic digestion followed by peptide mapping confirms the primary sequence and locates specific modifications. Quantitation in biological matrices typically uses liquid chromatography with tandem mass spectrometry after solid-phase extraction. Immunoassays are used less often, since antibody cross-reactivity with closely related peptides can bias results.
The peptide shares degradation routes common to modified peptides: deamidation of asparagine and glutamine residues, oxidation of methionine, and backbone hydrolysis under extreme pH. Lyophilized material is generally more stable than a solution, and residual water content directly affects the rate of hydrolysis. In liquid form, aggregation and visible particles can appear after agitation or repeated freeze-thaw cycles. Stability studies therefore track monomer content, aggregate content, and potency over months under defined temperature and humidity.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography for the main peak and with mass spectrometry for the observed molecular mass. Peptide mapping after enzymatic digestion confirms the primary sequence, while amino acid analysis provides a quantitative composition check. Size-exclusion chromatography and ion-exchange chromatography are used to look for aggregates and charge variants. Water content, residual solvents, and counter-ion content are measured separately, since a lyophilised powder is often reported on an as-is basis unless a correction is applied.
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
Solid tirzepatide is handled as a lyophilised, hygroscopic peptide powder that should be kept desiccated, protected from light, and stored frozen, typically at or below minus twenty degrees Celsius for long-term retention. Material left at ambient temperature for extended periods can take up moisture, which promotes aggregation and deamidation. Commercial liquid presentations are kept refrigerated between two and eight degrees Celsius and are not frozen. Reconstituted laboratory solutions are generally held cold and used within a short window because hydrolysis and oxidation continue slowly in solution.
These bound antibody/antigen complexes are then added to an antigen-coated well. The plate is washed, so unbound antibodies are removed. (The more antigen in the sample, the more Ag-Ab complexes are formed and so there are less unbound antibodies available to bind to the antigen in the well, hence "competition".) The secondary antibody, specific to the primary antibody, is added. This second antibody is coupled to the enzyme. A substrate is added, and remaining enzymes elicit a chromogenic or fluorescent signal. The reaction is stopped to prevent eventual saturation of the signal. Some competitive ELISA kits include enzyme-linked antigen rather than enzyme-linked antibody. The labeled antigen competes for primary antibody binding sites with the sample antigen (unlabeled). The less antigen in the sample, the more labeled antigen is retained in the well and the stronger the signal. Commonly, the antigen is not first positioned in the well. For the detection of HIV antibodies, the wells of microtiter plate are coated with the HIV antigen. Two specific antibodies are used, one conjugated with enzyme and the other present in serum (if serum is positive for the antibody). Cumulative competition occurs between the two antibodies for the same antigen, causing a stronger signal to be seen. Sera to be tested are added to these wells and incubated at 37 °C, and then washed. If antibodies are present, the antigen-antibody reaction occurs. No antigen is left for the enzyme-labelled specific HIV antibodies. These antibodies remain free upon addition and are washed off during washing.
While BIA Separations was the first to commercially market polymeric monoliths, Merck KGaA was the first company to market silica monoliths. In 1996, Tanaka and coworkers at the Kyoto Institute of Technology published extensive work on silica monolith technologies. Merck was later issued a license from Kyoto Institute of Technology to develop and produce the silica monoliths. Promptly thereafter, in 2001, Merck introduced its Chromolith line of monolithic HPLC columns at analytical instrumentation trade show PittCon. Initially, says Karin Cabrera, senior scientist at Merck, the high flow rate was the selling point for the Chromolith line. Based on customer feedback, though, Merck soon learned that the columns were more stable and longer-lived than particle-packed columns. The columns were the recipients of various new product awards. Difficulties in production of the silica monoliths and tight patent protection have precluded attempts by other companies at developing a similar product. It has been noted that there are more patents concerning how to encapsulate the silica rod than there are on the manufacture of the silica itself. Historically, Merck has been known for its superior chemical products, and, in liquid chromatography, for the purity and reliability of its particulate silica. Merck is not known for its LC columns. Five years after the introduction of its Chromolith line, Merck made a very strategic marketing decision.
Produced by Mike Tomlinson, made by Orlando Television Productions with WGBH 21 October The Mind Benders, in May 1991, the Broadcasting Complaints Commission, ruled that this episode should have been broadcast under the title Open Mind; about the Hemi-Sync method; the Float Centre, in St John's Wood with Samantha O'Connor, which cost £22 an hour; Peter Fenwick and flotation tanks; the EEG Mind Mirror of Geoffrey Blundell; the voice of Robert Monroe, and a hemi-sync session in Cambridge, where 200hz is played in one ear, and 206hz in the other ear; a so-called mind gymnasium in Japan, launched in 1975; Australian psychologist Dorothy Rowe, who questioned the veracity of the methods, which could be explained through the placebo effect, which is often not an unimportant effect on health. Narrated by Peter Jones, produced by Patrick Uden, directed by Gary Burczak, made by Uden Associates. Much of the techniques demonstrated were not dissimilar to techniques advocated by the 1990s Natural Law Party 28 October The Winning Streak, about East German methods in women athletics; with Katrin Krabbe. Narrated by Tony Ward, produced by Mike Johnstone, directed by Nikolas L.
, as in "Notation"), which are non-linear polynomial functions of δD and δ13C values. Such non-linearity can be a diagnostic signature for mixing if multiple samples of various mixing ratios can be measured. When end-members have similar δ13C or δD compositions, the non-linearity is negligible.
== Politics == Manmohan Singh (1933–2024), former Prime Minister of India from 2004 to 2014 Ajit Pal Singh Kohli, Indian politician and MLA from Patiala Assembly constituency Amolak Rattan Kohli (born 1942), former governor of the Indian state of Mizoram from 2001 to 2006 Om Prakash Kohli (1935–2023), former governor of the Indian state of Gujarat from 2014 to 2019 Abdul Ghani Kohli (born 1943), Indian J&K politician Mohammad Aslam Kohli, Indian J&K politician Krishna Kohli (born 1979), Pakistani politician (While her name is spelled as Kohli, she originates from the Koli people, who are unrelated to the Kohlis of the Khukhrain clan) Kuli Kohli (born 1970), Indian-British poet, writer, disabled activist and local council member Veeru Kohli (1964–2023), Pakistani human rights activist (While her name is spelled as Kohli, she originates from the Koli people, who are unrelated to the Kohlis of the Khukhrain clan)
Sources: en.wikipedia.org
=== Foreign policy === Gallrein supported the 2026 U.S. intervention in Venezuela. Commenting on the 2026 Iran War, Gallrein said on X on February 28, 2026, that the United States' attack on Iran: "sends a clear message to the world: The United States will not sit back while a hostile regime continually threatens our Nation, our allies, and global stability as Iran has for decades as the leading state sponsor of terrorism been responsible for the death of U.S. citizens and servicemembers.... Decisive action, clear objectives, and overwhelming strength save American lives and prevent larger wars, death, and destruction."
The trees can be harvested for their crimson red resin, called dragon's blood, which was highly prized in the ancient world and is still used today. Around the Mediterranean basin it is used as a dye and as a medicine, Socotrans use it ornamentally as well as dyeing wool, gluing pottery, a breath freshener, and lipstick. The root yields a gum-resin, used in gargle water as a stimulant, astringent and in toothpaste. The root is used in rheumatism, the leaves are a carminative. In 1883, the Scottish botanist Isaac Bayley Balfour identified three grades of resin: the most valuable were tear-like in appearance, then a mixture of small chips and fragments, with a mixture of fragments and debris being the cheapest. The resin of D. cinnabari is thought to have been the original source of dragon's blood until during the medieval and renaissance periods when other plants were used instead. Because of the belief that it is the blood of the dragon it is also used in ritual magic and alchemy. The local inhabitants of the city in the Socotra Island used the dragon's blood resin as a cure-all. Greeks, Romans, and Arabs used it in general wound healing, as a coagulant, cure for diarrhea, for dysentery diseases, for lowering fevers. It was also taken for ulcers in the mouth, throat, intestines and stomach. Dragon's blood from D. cinnabari was used as a source of varnish for 18th-century Italian violin-makers. It was also used as tooth-paste in the 18th century. It is still used as varnish for violins and for photoengraving.
For example, an officer of unit "A" does not directly command lower-ranking members of unit "B", and is generally expected to approach an officer of unit "B" if he requires action by members of that unit. The chain of command means that individual members take orders from only one superior and only give orders to a defined group of people immediately below them. If an officer of unit "A" does give orders directly to a lower-ranked member of unit "B", it would be considered highly unusual (i.e., a faux pas, or extraordinary circumstances, such as a lack of time or inability to confer with the officer in command of unit "B") as officer "A" would be seen as subverting the authority of the officer of unit "B". Depending on the situation or the standard procedure of the military organization, the lower-ranked member being ordered may choose to carry out the order anyway, or advise that it has to be cleared with their own chain of command first, which in this example would be with officer "B". Refusal to carry out an order is almost always considered insubordination; the only exception usually allowed is if the order itself is illegal (i.e., the person carrying out the order would be committing an illegal act). (See superior orders.) In addition, within combat units, line officers are in the chain of command, but staff officers in specialist fields (such as medical, dental, legal, supply, and chaplain) are not, except within their own specialty.
== Composition == Royal jelly is 67% water, 12.5% protein, 11% simple sugars (monosaccharides), 6% fatty acids and 3.5% 10-hydroxy-2-decenoic acid (10-HDA). It also contains trace minerals, antibacterial and antibiotic components, pantothenic acid (vitamin B5), pyridoxine (vitamin B6) and trace amounts of vitamin C, but none of the fat-soluble vitamins: A, D, E or K.
A positive result, in the absence of unequivocal high blood sugar, should be confirmed by a repeat of any of the above methods on a different day. It is preferable to measure a fasting glucose level because of the ease of measurement and the considerable time commitment of formal glucose tolerance testing, which takes two hours to complete and offers no prognostic advantage over the fasting test. According to the current definition, two fasting glucose measurements at or above 7.0 mmol/L (126 mg/dL) is considered diagnostic for diabetes mellitus. Per the WHO, people with fasting glucose levels from 6.1 to 6.9 mmol/L (110 to 125 mg/dL) are considered to have impaired fasting glucose. People with plasma glucose at or above 7.8 mmol/L (140 mg/dL), but not over 11.1 mmol/L (200 mg/dL), two hours after a 75 gram oral glucose load are considered to have impaired glucose tolerance. Of these two prediabetic states, the latter in particular is a major risk factor for progression to full-blown diabetes mellitus, as well as cardiovascular disease. The American Diabetes Association (ADA) since 2003 uses a slightly different range for impaired fasting glucose of 5.6 to 6.9 mmol/L (100 to 125 mg/dL). Glycated hemoglobin is better than fasting glucose for determining risks of cardiovascular disease and death from any cause.
Sources: en.wikipedia.org
It is a synthetic peptide that activates both the GIP and GLP-1 receptors, making it a dual agonist. Approved products are given by injection rather than by mouth. It is not a small molecule and does not belong to the older sulfonylurea or thiazolidinedione families.
Engaging two receptors recruits signaling pathways that only partly coincide. This can shift the magnitude of effects on insulin release, glucagon levels and appetite relative to selective agents. Whether the pairing delivers benefits beyond a simple sum of the two is still debated in the literature.
The proportional contribution of each receptor to observed clinical effects has not been fully separated. Long-term consequences of continuous dual stimulation are likewise unclear. Investigators continue to probe these points through laboratory and clinical work.
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.